PCN8 COMPARING PATIENT-RELEVANT ENDPOINT WITH CLINICAL ENDPOINT IN A RARE DISEASE: THE CASE OF METASTATIC MERKEL CELL CARCINOMA TREATED WITH AVELUMAB

Abstract

In this international, single-arm, open-label, multicenter, phase 2 trial (NCT02155647), treatment-naive patients with metastatic Merkel cell carcinoma (MCC) received avelumab 10 mg/kg treatment every 2 weeks with a follow-up of ≥15 months. In this preplanned sub-analysis, a patient-relevant endpoint of health-related quality of life (HRQOL) deterioration-free survival (QFS) was evaluated in relation to the typically used clinical endpoint, progression-free survival (PFS).